Printer Friendly

Psyadon Pharmaceuticals, Inc. Announces Dr. William Nyhan's Participation in the Clinical Trial of Ecopipam in Lesch-Nyhan Disease.

GERMANTOWN, Md. -- Psyadon Pharmaceuticals, Inc. announces today the opening of a clinical research site at the University of California at San Diego headed by Dr. William Nyhan. He joins Dr. Hyder Jinnah at Emory University to study the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with Lesch-Nyhan Disease (LND).

Dr. Nyhan (in collaboration with Dr. Michael Lesch) was the first to definitively report this disease in 1964, and his subsequent work over the last four decades on LND's biological basis has earned him worldwide recognition. LND is a rare genetic disorder that is predominantly seen in males. The patients have a well-studied mutation of a specific enzyme which causes a characteristic metabolic, motor, and behavioral syndrome. The onset of the disease is usually between ages 1-3 years, and patients suffer life-long debilitation. It has been estimated that there are between 500 and 1000 patients in the United States. There are currently no treatments available for these patients.

"The dopaminergic system is the best studied link between the enzyme defect and the clinical manifestations of LND," notes Dr. Nyhan. "Since ecopipam works selectively on the dopaminergic system, I believe it has the potential to significantly impact the disease, and I am very excited to participate in the clinical trial."

"We are thrilled to have Dr. Nyhan joining the clinical investigators studying ecopipam in patients with Lesch-Nyhan Disease. His enthusiasm for the study is further validation of our approach to treating this disease, and we look forward to the valuable insight that Dr. Nyhan will bring to the program," said Richard E. Chipkin, PhD, President and CEO of Psyadon Pharmaceuticals.

Ecopipam is a selective antagonist of the D1-family of dopamine receptors and has already been studied in over 2,000 patients. Psyadon Pharmaceuticals licensed worldwide rights to ecopipam from Schering-Plough Corporation, an affiliate of Merck & Co., Inc. in 2008.


Psyadon Pharmaceuticals has received orphan drug designation for the use of ecopipam in LND in both the United States and the European Union. This provides market exclusivity and other benefits in these territories.


Psyadon Pharmaceuticals is a pharmaceutical company dedicated to the discovery and development of drugs for serious neurological and psychiatric disorders. The company was founded in 2004 under the name Ruxton Pharmaceuticals.
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 9, 2010
Previous Article:Life Time Fitness to Present at the William Blair & Company 30th Annual Growth Stock Conference.
Next Article:MGEN Selects SAS to Optimize Operational Risk Management Program.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters